Department of Ophthalmology, The People's Hospital of Chongqing Liangjiang New Area, Chongqing, China.
Medicine (Baltimore). 2023 Aug 4;102(31):e34170. doi: 10.1097/MD.0000000000034170.
Ranibizumab addition may benefit to improve the efficacy in patients with diabetic retinopathy than only photocoagulation, and this meta-analysis aims to explore the impact of ranibizumab addition on efficacy for diabetic retinopathy.
PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials assessing the effect of ranibizumab addition on patients with diabetic retinopathy for this meta-analysis.
Six randomized controlled trials were finally included in the meta-analysis. Overall, compared with control intervention for diabetic retinopathy, ranibizumab addition showed significantly increased number of neovascularization area reduction (OR = 4.20; 95% CI = 1.47-12.02; P = .007) and reduced fluorescein leakage (MD = -2.53; 95% CI = -3.31 to -1.75; P < .00001), but showed no obvious impact on neovascularization area (MD = -1.80; 95% CI = -3.68 to 0.08; P = .06), photocoagulation retreatment (OR = 1.03; 95% CI = 0.47-2.27; P = .94) or adverse events (OR = 1.45; 95% CI = 0.49-4.29; P = .50).
Ranibizumab combined with photocoagulation is effective to improve efficacy for diabetic retinopathy.
与单纯光凝相比，雷珠单抗的加入可能有助于提高糖尿病性视网膜病变的疗效，本荟萃分析旨在探讨雷珠单抗的加入对糖尿病性视网膜病变疗效的影响。
系统检索 PubMed、EMbase、Web of science、EBSCO 和 Cochrane 图书馆数据库，纳入评估雷珠单抗加入治疗糖尿病性视网膜病变患者效果的随机对照试验进行本荟萃分析。
最终有 6 项随机对照试验纳入荟萃分析。总体而言，与糖尿病性视网膜病变的对照干预相比，雷珠单抗的加入显著增加了新生血管面积减少的数量（OR = 4.20；95% CI = 1.47-12.02；P =.007）和减少荧光素渗漏（MD = -2.53；95% CI = -3.31 至 -1.75；P <.00001），但对新生血管面积（MD = -1.80；95% CI = -3.68 至 0.08；P =.06）、光凝再治疗（OR = 1.03；95% CI = 0.47-2.27；P =.94）或不良事件（OR = 1.45；95% CI = 0.49-4.29；P =.50）无明显影响。
雷珠单抗联合光凝治疗可有效提高糖尿病性视网膜病变的疗效。
